Get the Stockscreener App
2.21
5.24%
0.11
After Hours:
2.18
-0.03
-1.36%
Akebia Therapeutics Inc stock is traded at $2.21, with a volume of 6.11M.
It is up +5.24% in the last 24 hours and down -19.05% over the past month.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
See More
Previous Close:
$2.10
Open:
$2.11
24h Volume:
6.11M
Relative Volume:
1.56
Market Cap:
$585.97M
Revenue:
$194.75M
Net Income/Loss:
$-51.26M
P/E Ratio:
-7.8929
EPS:
-0.28
Net Cash Flow:
$-23.38M
1W Performance:
-27.06%
1M Performance:
-19.05%
6M Performance:
-8.30%
1Y Performance:
+33.13%
1-Day Range:
$2.07
$2.23
1-Week Range:
$2.065
$3.20
52-Week Range:
$1.52
$4.0787
Akebia Therapeutics Inc Stock (AKBA) Company Profile
Name
Akebia Therapeutics Inc
Sector
Phone
617-871-2098
Address
245 FIRST STREET, CAMBRIDGE, MA
Compare AKBA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AKBA
Akebia Therapeutics Inc
|
2.21 | 556.80M | 194.75M | -51.26M | -23.38M | -0.28 |
|
ZTS
Zoetis Inc
|
144.09 | 63.86B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.44 | 41.80B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.27 | 40.88B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.48 | 22.98B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
445.43 | 19.53B | 3.08B | 1.24B | 1.07B | 25.61 |
Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-04-25 | Resumed | H.C. Wainwright | Buy |
| Apr-28-25 | Initiated | Leerink Partners | Outperform |
| Apr-01-25 | Initiated | Jefferies | Buy |
| Nov-29-23 | Resumed | BTIG Research | Buy |
| Aug-28-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-31-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-31-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-31-22 | Downgrade | Mizuho | Buy → Neutral |
| Mar-31-22 | Downgrade | Needham | Buy → Hold |
| Mar-31-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Mar-08-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-21 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-14-19 | Reiterated | Needham | Buy |
| Aug-06-19 | Reiterated | H.C. Wainwright | Buy |
| Jul-11-19 | Reiterated | H.C. Wainwright | Buy |
| May-02-19 | Initiated | JP Morgan | Overweight |
| Mar-20-19 | Initiated | Citigroup | Neutral |
| Sep-07-18 | Resumed | Morgan Stanley | Equal-Weight |
| Aug-10-18 | Reiterated | Needham | Buy |
| Jun-06-18 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-17 | Initiated | Piper Jaffray | Overweight |
| Dec-07-17 | Initiated | BTIG Research | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Sector Perform |
| Jul-10-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-27-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-27-17 | Reiterated | Needham | Buy |
| Dec-27-16 | Reiterated | H.C. Wainwright | Buy |
| Dec-20-16 | Reiterated | JMP Securities | Mkt Outperform |
| Nov-15-16 | Initiated | Aegis Capital | Buy |
| Sep-29-16 | Initiated | Brean Capital | Buy |
| Mar-16-16 | Reiterated | Needham | Buy |
| Jan-21-16 | Initiated | Credit Suisse | Neutral |
View All
Akebia Therapeutics Inc Stock (AKBA) Latest News
Akebia Therapeutics (NASDAQ:AKBA) Stock Price Up 7.4%Here's Why - MarketBeat
Akebia Therapeutics (NASDAQ:AKBA) Price Target Lowered to $6.00 at HC Wainwright - MarketBeat
Akebia plummets as it abandons Vafseo for non-dialysis patients - MSN
Analysts Offer Insights on Healthcare Companies: Atricure (ATRC), Tectonic Therapeutic (TECX) and Akebia Therapeutics (AKBA) - The Globe and Mail
Is Akebia Therapeutics Inc. (AX9) stock undervalued at current priceQuarterly Market Summary & Verified Momentum Stock Alerts - newser.com
How high can Akebia Therapeutics Inc. stock goWeekly Profit Analysis & Expert Curated Trade Setup Alerts - newser.com
Akebia Therapeutics (AKBA) Expected to Announce Earnings on Thursday - MarketBeat
Is this a good reentry point in Akebia Therapeutics Inc.2025 Support & Resistance & Fast Gaining Stock Reports - newser.com
How Akebia Therapeutics Inc. stock reacts to job market dataJobs Report & Momentum Based Trading Signals - newser.com
Is Akebia Therapeutics Inc. (AX9) stock attractive for growth fundsJuly 2025 Pullbacks & AI Forecasted Entry and Exit Points - newser.com
How rising interest rates impact Akebia Therapeutics Inc. stockWeekly Stock Summary & Risk Adjusted Buy and Sell Alerts - newser.com
Can Akebia Therapeutics Inc. stock sustain revenue growth2025 Buyback Activity & Consistent Profit Alerts - newser.com
Why Akebia Therapeutics Inc. (AX9) stock attracts wealthy investorsJuly 2025 Technicals & Real-Time Volume Analysis Alerts - newser.com
Will Akebia Therapeutics Inc. stock attract more institutional investorsWeekly Trade Recap & Weekly Hot Stock Watchlists - newser.com
Is Akebia Therapeutics Inc. (AX9) stock attractive for dividend growthJuly 2025 News Drivers & Expert Verified Stock Movement Alerts - newser.com
Akebia Therapeutics (AKBA) Is Down 29.9% After Ending VALOR Trial for Non-Dialysis CKD Patients - Yahoo Finance
Akebia Therapeutics (NASDAQ:AKBA) Price Target Lowered to $5.00 at BTIG Research - MarketBeat
Akebia Therapeutics (NASDAQ:AKBA) Shares Gap DownHere's Why - MarketBeat
How Akebia Therapeutics Inc. stock trades during market volatilityInsider Buying & Stepwise Trade Signal Guides - newser.com
Akebia Therapeutics (AKBA) Receives Revised Price Target from HC Wainwright & Co. | AKBA Stock News - GuruFocus
Akebia Therapeutics to Report Third Quarter 2025 Financial Results and Discuss Recent Business Highlights - MarketScreener
HC Wainwright & Co. Maintains Akebia Therapeutics (AKBA) Buy Recommendation - Nasdaq
How strong dollar benefits Akebia Therapeutics Inc. (AX9) stock2025 Big Picture & Fast Gain Swing Alerts - newser.com
Strategic Shift and Market Opportunities Drive Buy Rating for Akebia Therapeutics - TipRanks
Akebia price target lowered to $6 from $8 at H.C. Wainwright - TipRanks
Will Akebia Therapeutics Inc. stock benefit from sector rotationJuly 2025 Breakouts & High Yield Equity Trading Tips - newser.com
Will Akebia Therapeutics Inc. (AX9) stock profit from AI boomTrade Risk Report & AI Based Buy and Sell Signals - newser.com
Health Care Down on Mixed EarningsHealth Care Roundup - MarketScreener
BTIG Lowers Akebia Therapeutics (AKBA) Price Target by 50% | AKB - GuruFocus
Why Is Akebia Therapeutics Stock Plunging TodayAkebia Therapeutics (NASDAQ:AKBA) - Benzinga
Akebia Therapeutics: Dialysis-Only Path Puts VOCAL/Protocol Wins At The Core (NASDAQ:AKBA) - Seeking Alpha
Akebia Therapeutics’ Pediatric Anemia Study Withdrawn: Market Implications - TipRanks
Akebia stock plunges as kidney drug expansion plans scrapped - The Business Journals
Akebia scraps plan for Vafseo trial after discussions with FDA - Fierce Pharma
Akebia Therapeutics Stock Slumps After FDA Meeting Ends Without Path Forward for Vafseo Label Expansion - Stocktwits
Akebia stock tumbles after FDA meeting on vadadustat trial design By Investing.com - Investing.com Canada
Akebia Abandons Non-Dialysis Trial For Vafseo On Likely Higher Costs - Citeline News & Insights
Mondelez International, Stride, Varonis Systems And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Morning Market Movers: CMBM, LRN, VRNS, AKBA See Big Swings - RTTNews
FDA setback prompts Akebia to give up on broader Vafseo label - The Pharma Letter
Akebia Therapeutics Stock Up 14%, Buy Or Wait? - Trefis
Why Teradyne Shares Are Trading Higher By More Than 20%; Here Are 20 Stocks Moving Premarket - Benzinga
Will earnings trigger a reversal in Akebia Therapeutics Inc.July 2025 Breakouts & Long Hold Capital Preservation Plans - newser.com
Why institutional investors increase stakes in Akebia Therapeutics Inc. (AX9) stockAnalyst Downgrade & Long Hold Capital Preservation Tips - newser.com
Analyzing Akebia Therapeutics Inc. with risk reward ratio chartsPortfolio Return Report & Community Trade Idea Sharing - newser.com
Comparing Akebia Therapeutics Inc. in custom built stock radarsExit Point & AI Driven Price Predictions - newser.com
Is Halting Broad Vafseo Expansion Shifting the Investment Outlook for Akebia Therapeutics (AKBA)? - simplywall.st
Akebia Therapeutics Stock Rallied 16%Have You Assessed the Risk - Trefis
Akebia Therapeutics (AKBA) Halts Expansion Plans for Vafseo - GuruFocus
Akebia (AKBA) Adjusts Strategy Following FDA Meeting on Anemia T - GuruFocus
Earnings Beat: Will Akebia Therapeutics Inc. stock benefit from sector rotationMarket Performance Recap & Technical Pattern Alert System - Fundação Cultural do Pará
Akebia Therapeutics Inc Stock (AKBA) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.18%
1.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):